11 July 2024
BELLUSCURA PLC
("Belluscura" or the "Company")
Directorate Change
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Jonathan Satchell, Non-executive Director, has informed the Board that he intends to step down from his role as a Non-executive Director with effect from 11 July 2024.
Jonathan was appointed to the Board in February 2024 following the acquisition of TMT Acquisition plc by the Company.
Adam Reynolds, Chairman of Belluscura, commented:
"On behalf of the Board, I would like to thank Jonathan for his valued contribution during his time on the Board of Belluscura. His insights and advice have been greatly appreciated since he joined the Board following the Company's acquisition of TMT Acquisition plc and we wish him well with his other roles."
-Ends-
For further information please contact:
| Belluscura plc | Tel: +44 (0)20 3128 8100 |
| Adam Reynolds, Chairman | |
| | |
| SPARK Advisory Partners Limited Nominated Adviser | Tel: +44 (0)20 3368 3550 |
| Neil Baldwin / Jade Bayat | |
| | |
| Dowgate Capital Limited Broker | Tel: +44 (0)20 3903 7715 |
| Russell Cook / Nicholas Chambers | |
| | |
| MHP Financial PR & Investor Relations | Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
| Katie Hunt/Matthew Taylor | |
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.